TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04596189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 MG in 2 ML Prefilled Syringe
Description: The Dupilumab will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction.~Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas), the upper thighs or the upper arms, so that the same site is not injected twice consecutively. Injection in the upper arms could be done only by a trained person (caregiver trained by Investigator or Delegate) or health care professional but not the patients themselves.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The Placebo will be administered following clinic procedures and blood collection. Patients will be monitored at the study site for at least 30 minutes after injections for signs of hypersensitivity reaction.~Subcutaneous injection sites should be alternated among the 4 quadrants of the abdomen (avoiding navel and waist areas), the upper thighs or the upper arms, so that the same site is not injected twice consecutively. Injection in the upper arms could be done only by a trained person (caregiver trained by Investigator or Delegate) or health care professional but not the patients themselves.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Furoate nasal spray
Description: On a daily basis throughout the study, the patient will use a paper diary to record daily use of mometasone furoate nasal spray (MFNS) 50 μg/actuation nasal spray, suspension (refer to the package insert \& SmPC for a description, administration details and precautions for use). MFNS is provided in a bottle that contains 18 g (140 actuations) of product formulation. If patient is unable to tolerate 200 micrograms twice a day (total dose 400 micrograms) due to experiencing adverse event, patient may reduce dose to 200 micrograms once per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mometasone Furoate nasal spray
Description: On a daily basis throughout the study, the patient will use a paper diary to record daily use of mometasone furoate nasal spray (MFNS) 50 μg/actuation nasal spray, suspension (refer to the package insert \& SmPC for a description, administration details and precautions for use). MFNS is provided in a bottle that contains 18 g (140 actuations) of product formulation. If patient is unable to tolerate 200 micrograms twice a day (total dose 400 micrograms) due to experiencing adverse event, patient may reduce dose to 200 micrograms once per day.
Study: NCT05039099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP-101
Description: Participants receive AP-101 by intravenous infusion (IV).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants receive placebo by IV.
Study: NCT04925687

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal autologous CD34+ cells
Description: Autologous CD34+ cells harvested from bone marrow injected intravitreal
Study: NCT04800250

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment of gingival recessions
Description: Patients will have a surgery for their gingival recessions. They will be enrolled in the split mouth-study. They will have on one side mucogain matrix transplant, an on another side they will have the gold standard procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment of gingival recessions
Description: Patients will have a surgery for their gingival recessions. They will be enrolled in the split mouth-study. They will have on one side mucogain matrix transplant, an on another side they will have the gold standard procedure
Study: NCT05532826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: donor EBV-specific T lymphocytes
Description: EBV-DNA reactive after transplantation, or did not turn negative after +30 days, peripheral blood lymphocytes of the donor were collected to prepare EBV-CTL, and the first transfusion of EBV-CTL 6.0x105 was given at 48h to rapidly culture EBV-CTL, then EBV-CTL 6.0x105/kg was injected once a week untile EBV-DNA negative for 2 consecutive times or GVHD happened. After the second infusion, EBV-DNA did not decrease and there was no aGVHD patients, EBV-CTL infusion volume was increased to 1.2x106/kg, once a week. After 2 cycle infusion, EBV-DNA still did not decrease, and the reinfusion was terminated.~Peripheral blood lymphocytes were collected from donors of high-risk patients at +14 days after allogeneic hematopoietic stem cell transplantation to prepare EBV-CTL, and EBV-CTL 6.0x105/kg was infused at +21d, +28d, +35d and + 42D for prevention. During treatment, if the patient develops GVHD, the infusion should be stopped.
Study: NCT05936112

Intervention type: OTHER
Group type: OTHER
Intervention: Fecal calprotectin dosage
Description: Dosing calprotectin in infants' feces + questionnaire/interview with parents

Intervention type: OTHER
Group type: OTHER
Intervention: Fecal calprotectin dosage
Description: Dosing calprotectin in infants' feces + questionnaire/interview with parents

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire and interview with parents
Description: Dosing calprotectin in infants' feces + questionnaire/interview with parents

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire and interview with parents
Description: Dosing calprotectin in infants' feces + questionnaire/interview with parents
Study: NCT05932277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986419
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Specified dose on specified days
Study: NCT06050317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Plus mFFN and Radiation
Description: Sintilimab Plus mFFN and Radiation
Study: NCT04404231

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Delivery of infrared light to the head
Description: Building upon the experience gathered from previous depression clinical trials, we will treat twice weekly for a total of 4-week duration consisting of 8 sessions. Each treatment will last 20 min and areas irradiated will include frontal and temporal areas bilaterally. Irradiance of 250 mW/cm2 with a fluence of 60 J/cm2.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Delivery of infrared light to the head
Description: Building upon the experience gathered from previous depression clinical trials, we will treat twice weekly for a total of 4-week duration consisting of 8 sessions. Each treatment will last 20 min and areas irradiated will include frontal and temporal areas bilaterally. Irradiance of 250 mW/cm2 with a fluence of 60 J/cm2.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Delivery of infrared light to the head
Description: Building upon the experience gathered from previous depression clinical trials, we will treat twice weekly for a total of 4-week duration consisting of 8 sessions. Each treatment will last 20 min and areas irradiated will include frontal and temporal areas bilaterally. Irradiance of 250 mW/cm2 with a fluence of 60 J/cm2.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Infrared treatment
Description: This is sham treatment. No light is actually given.
Study: NCT01012986

Intervention type: OTHER
Intervention: Assessment of reading skills

Intervention type: OTHER
Intervention: Assessment of reading skills
Study: NCT06400914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens A (ocufilcon D)
Description: 15 minutes of daily wear.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens B (fanfilcon A)
Description: 15 minutes of daily wear.
Study: NCT05757986

Intervention type: OTHER
Intervention: The presence of nausea and vomiting within 24 hours after surgery
Description: This is a prospective risk prediction model building, thus there is no traditional definition of intervention.

Intervention type: OTHER
Intervention: The presence of nausea and vomiting within 24 hours after surgery
Description: This is a prospective risk prediction model building, thus there is no traditional definition of intervention.
Study: NCT06466694

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Modified Dialectical Behavioural Therapy
Description: The therapy will be co-delivered by the Elder, a perinatal psychiatrist and social worker trained in DBT. To evaluate through a patient lens content of the Dialectical Behavior Therapy (DBT) through the lens of an Indigenous Knowledge Carrier (Elder)
Study: NCT05553795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early removal of chest drain
Description: Chest drains are removed 3 hours after the end of surgery in absence of contraindications in arm A.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Chest drain
Description: The chest drains in arm B are removed during the further postoperative course according to standard algorithm.
Study: NCT06340308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol
Description: Patients will take 1 tablet of Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol
Description: Patients will take 2 tablets of Berberine-based Food Supplement, Artichoke Extract, Phytosterols, Fenugreek and SelectSIEVE® OptiChol for 12 weeks
Study: NCT04535024

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Description: We plan to irradiate as many metastatic lesions as possible, in the precondition that normal tissues can tolerate.~Target dose will be adjusted depending on site of the lesion and organs at risk (BED \> 100Gy).~Treatment schedule is once per day and five days per week. Sequence of irradiation for multiple metastases is at the discretion of the investigators based on their experience.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Starts within one week upon SABR completion: 200mg, d1, q3w; Continued until disease progression, unacceptable toxicity or patient withdrawal.
Study: NCT05311735

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Freeze-Dried Bone Allograft control
Description: Bone grafting to prevent alveolar ridge collapse after tooth removal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mineralized Dentin Graft
Description: Mineralized tooth graft used as a bone graft substitute to prevent alveolar ridge collapse after tooth removal

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial-Demineralized Dentin Graft
Description: Partially mineralized tooth graft used as a bone graft substitute to prevent alveolar ridge collapse after tooth removal
Study: NCT04500795

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Middle meningeal artery embolization
Description: MMA embolization will be performed with a liquid embolization agent with local anaesthesia. Selective angiography will be performed before embolization to select MMA branch targets and detect potentially dangerous collateral vessels. If no dangerous collaterals are found, MMA branches supplying to the dura of convexity will be targeted and embolized according to findings of the selective angiography using a liquid embolization agent. If dangerous collaterals are identified, the microcatheter will be advanced more distally or the collaterals will be coiled prior to embolization. Procedure will be concluded once the flow stasis of MMA is confirmed. Embolization is considered successful if all MMA targets are embolized without procedural complications.~Patients with existing use of antiplatelet or anticoagulation medication will not undergo medication reversal for the embolization procedure.
Study: NCT06020053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: saline irrigation at various temperatures (4°C, 25°C)
Description: cold serum application
Study: NCT05016466

Intervention type: OTHER
Intervention: Standard Care
Description: Patients will followed during 5 years, and only 2 visits , baseline and 5 years

Intervention type: OTHER
Intervention: Standard Care plus oxidative stress study plus inflammation biomarkers study
Description: Patients will followed during 5 years, Annual follo-up visits will be carried out during this period
Study: NCT05297669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Felbinac Trometamol Injection
Description: Felbinac Trometamol Injection diluted to 100 ml with 0.9% sodium chloride injection.Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min)..~One dose at 8h and 16h after the start of the first dose,the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo diluted to 100 ml with 0.9% sodium chloride injection. Use a micro-injection pump to inject intravenously at a constant speed for 30 min (± 2 min).~One dose at 8h and 16h after the start of the first dose, the first intravenous infusion was started at 30±5 minutes before the end of the operation (Skin suture completes the last stitch).The drug was given 3 times,3 times/day, once every 8 hours.
Study: NCT05514041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline solution
Description: OC-01 nasal spray 0.03 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo nasal spray (OC-01 Vehicle Nasal Spray)
Description: Placebo nasal spray (OC-01 Vehicle Nasal Spray)
Study: NCT04897750

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CT001
Description: Sufentanil 0.5 mcg/kg + ketamine 0.5 mg/kg as nasal spray, followed by an additional dose 10 -15 minutes after, if needed.
Study: NCT04702529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment of hypertrophic scars (Soliton's Rapid Acoustic Pulse (RAP) Device)
Description: Administration of 3 Rapid Acoustic Pulse (RAP) treatments
Study: NCT06021639

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: The last 24 hours will consume low fiber food.
Description: White bread, white rice, plain pasta or noodles, cereals not containing more than 1 gram of fiber per serving., canned or cooked skinless and seedless fruit, skinless and seedless raw fruit, pulp-free or low-fiber fruit or vegetable broth, seedless, seedless, skinless, such as canned or well-cooked carrots, string beans or peppers vegetables, tender red meat, poultry and fish, eggs, no more than two tablespoons per day, soft (creamy) peanut butter, milk, yogurt or plain cheese, salad dressings without oils or nuts, desserts without nuts.
Study: NCT06231654

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote photoplethysmography for physiological parameters
Description: Patients participating in the study will be recruited from our emergency department.~The child will be placed in a dedicated, quiet, well-lit office with their parents. The following data are then collected: sex, age, phototype according to Fitzpatrick's classification. The child sits in a chair facing a camera connected to a laptop running Caducy® Medical Device software. At the same time, and following the usual procedure, three ECG electrodes will be positioned on the patient. The whole device is connected to our standard device. Once the child is immobile and ready, the Caducy® application is launched. At the same time, our standard device is activated. After 30 seconds, we will collect the HR and FR values revealed by the Caducy® application via the non-contact plethysmography method. On the other hand, it will collect the HR and FR values revealed by our standard device (Mindray® scope).
Study: NCT05820165

Intervention type: RADIATION
Intervention: high-resolution 3D-T1
Description: Subjects undergo a high-resolution 3D-T1 imaging to obtain structural images
Study: NCT05058807

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole body vibration group
Description: Experimental Group will receive WBV training and balance exercises under the supervision of a physical therapist by using a vibration platform. Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps \* 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps, with 30 sec rest interval~WHOLE BODY VIBRATION:~The patient stood on the platform with his/her feet barefoot shoulder width and stared at the front, delivered on a side alternating vibration platform in an intermittent way: five repetitions of 1 min vibration followed by a 1 min rest. The vibration frequency and amplitude were 20 Hz and 3.0 mm respectively.~These outcomes will be evaluated at baseline, and after 4 week and at 8th week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi group
Description: Control group will receive Balance exercises include:~Double leg stance with eyes open and eyes closed 10 Reps \* 3 minutes Tandem walk for 3 minutes Sideways walk for 3 minutes Single leg stance for 1 minute with 5 Reps ,with 30 sec rest interval Yang style Tai chi exercise which consist of 10 positions. 1. Hold the ball ward off 2: Grasping the sparrows tail left; 3.Grasping the sparrows tail Right;; 5.Repulse Monkey; 6. Part wild horse's Mane; 7.Brush knee Twist step; 8.Lift kick left; 9.Lift kick Right; 10.Cross hands with double leg stance~1st and 2nd week will last for 5reps, 3rd and 4th week will last for 10reps,5th and 6th week will last for 15reps,7th and 8th week will last for 20reps, starting with 10 minutes warming- up and ending with 10 minutes cool-down. These outcomes will be evaluated at baseline, and after 4 week and at 8th week
Study: NCT05094726

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: photobiomodulation
Description: Photobiomodulation (PBM) describes the use of red or near-infrared light to stimulate, heal, regenerate, and protect tissue that has either been injured, is degenerating, or else is at risk of dying.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo intervention by photobiomodulation device
Description: placebo intervention while the photobiomodulation device is on the off mode
Study: NCT06156371

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lymphatic drainage massage
Description: Before the application, the patient will be placed in a supine position and the feet will be elevated to 45 degrees by the researcher. After the infraclavicular lymph node, located at the point where the veins in the neck area meet the thymus gland, is stimulated with a pumping action, lower extremity applications will be started in the form of upper legs, lower legs and feet; By stimulating the inguinal lymph node in the upper leg application, the popliteal lymph node in the lower leg application, and the medial malleolus lymph node in the foot application, the mobility of the lymph fluid in the direction of the stimulated lymph node is used using stroking, pumping, circular movements or rolling movements according to the weight characteristic, body type and preference of the patient. will be provided. Finally, passive exercise will be performed 5 times, repeating both legs in flexion and extension positions, and the infraclavicular lymph node will be stimulated.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: classic massage
Description: The application will be done by the researcher. The order of application is upper leg, lower leg and feet. During the application, appropriate methods such as effleurage (stroking), kneading, friction, impact and vibration will be used. The application will start with efflorescence and end with the same technique. To the upper leg; Starting from the knee to the groin, to the lower leg; The application will be made in the direction of the muscle fibers, starting from the ankle to the knee. Appropriate techniques will be used depending on the characteristics of the application areas, and each technique will be repeated 5-10 times. In the final stage, passive exercise will be performed by moving to the foot and applying flexion and extension to the ankle 5 times. The application will be completed by applying similar applications to the upper and lower legs on the back of the foot and the outer and lower surface of the foot. Olive oil will be used as essential oil during application.